Sinovac Biotech LtdSVA
What Sinovac Biotech Ltd does.
We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus..
• 2002: Launched Healive (Hepatitis A Vaccine, Inactivated), the first of its kind developed by a China-based manufacturer. Healive subsequently passed WHO prequalification in 2017.
• 2005: Obtained approvals for Bilive (Hepatitis A and B Combined Vaccine) and Anflu (Influenza Vaccine (Split Virion), Inactivated).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $510.6M | $19.4B | $1.5B | $470.2M | $361.4M | $386.0M |
| Net income | $110.4M | $8.1B | $14.5M | -$13.5M | $90.9M | -$59.7M |
| Free cash flow | $351.8M | $14.7B | -$1.1B | -$17.5M | -$152.9M | -$561.1M |
More on SVA.
- Sinovac Biotech Ltd summary
- Sinovac Biotech Ltd financial statements
- Sinovac Biotech Ltd key metrics
- Sinovac Biotech Ltd health scores and style box
- Sinovac Biotech Ltd earnings
- Sinovac Biotech Ltd dividends
- Sinovac Biotech Ltd valuation
- Sinovac Biotech Ltd ownership and insiders
- Sinovac Biotech Ltd peers
Figures from Sinovac Biotech Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.